What is the Lawsuit Against Depo-provera?

The antidepressant and contraceptive Depo-Provera (medroxyprogesterone acetate) is currently the subject of product liability lawsuits alleging that Pfizer, the manufacturer, failed to adequately warn users about an increased risk of developing brain tumors.

Key aspects of the litigation include:

Medical Links: Recent studies, including a 2024 JAMA analysis, suggest that long-term use of this progestin-based injectable can lead to a significantly higher risk of developing meningiomas. These are typically benign but life-altering brain tumors that are sensitive to hormones.

Legal Claims: Plaintiffs allege that Pfizer had internal knowledge of these risks from various studies but did not disclose the dangers to the public or update safety labels in a timely manner. Most claims are based on theories of design defects and failure to warn.

Multidistrict Litigation (MDL): Federal cases have been consolidated into MDL No. 3140 in the U.S. District Court for the Northern District of Florida. This allows for streamlined discovery and pretrial proceedings for claimants across the country.

Eligibility: Generally, individuals who used Depo-Provera for a prolonged period (often more than two years) and received a confirmed diagnosis of a brain tumor or meningioma via MRI or CT scans may be eligible to join the litigation.

Compensation: Lawsuits seek to recover damages for medical expenses, lost wages (including temporary or permanent earning reductions), pain and suffering, and potential punitive damages.